Cristina Gonzalez-Echavarri1, Irama Villar2, Amaia Ugarte2, Rosa Larrieta2, Guillermo Ruiz-Irastorza2. 1. From the Autoimmune Diseases Research Unit, Department of Internal Medicine, and the Department of Obstetrics, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Universidad del País Vasco (UPV)/ Euskal Herriko Unibertsitatea (EHU), Bizkaia, Spain.C. Gonzalez-Echavarri, MD, Senior Registrar; I. Villar, MD, Consultant Physician; A. Ugarte, MD, Consultant Physician; G. Ruiz-Irastorza, MD, PhD, Professor of Medicine, Head of the Autoimmune Diseases Research Unit, Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, UPV/EHU; R. Larrieta, MD, Consultant Physician, Department of Obstetrics, BioCruces Health Research Institute, Hospital Universitario Cruces. cristina.glzdeechavarri@gmail.com. 2. From the Autoimmune Diseases Research Unit, Department of Internal Medicine, and the Department of Obstetrics, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Universidad del País Vasco (UPV)/ Euskal Herriko Unibertsitatea (EHU), Bizkaia, Spain.C. Gonzalez-Echavarri, MD, Senior Registrar; I. Villar, MD, Consultant Physician; A. Ugarte, MD, Consultant Physician; G. Ruiz-Irastorza, MD, PhD, Professor of Medicine, Head of the Autoimmune Diseases Research Unit, Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, UPV/EHU; R. Larrieta, MD, Consultant Physician, Department of Obstetrics, BioCruces Health Research Institute, Hospital Universitario Cruces.
Abstract
OBJECTIVE: To determine the prevalence of antiphospholipid antibodies (aPL) and their association with obstetric outcomes in women with preeclampsia. METHODS: The study included 150 patients. Clinical variables, risk factors, and severity criteria for preeclampsia and aPL were analyzed. RESULTS: We found aPL in 4% of patients without risk factors for preeclampsia and in no women with risk factors (p = 0.03). Fifty percent of aPL-positive patients had a fetus with intrauterine growth restriction versus 13.9% (p = 0.04). No relation between aPL and severe preeclampsia was found. CONCLUSION: The prevalence of aPL among women with preeclampsia is low. aPL can predispose women without risk factors to preeclampsia.
OBJECTIVE: To determine the prevalence of antiphospholipid antibodies (aPL) and their association with obstetric outcomes in women with preeclampsia. METHODS: The study included 150 patients. Clinical variables, risk factors, and severity criteria for preeclampsia and aPL were analyzed. RESULTS: We found aPL in 4% of patients without risk factors for preeclampsia and in no women with risk factors (p = 0.03). Fifty percent of aPL-positive patients had a fetus with intrauterine growth restriction versus 13.9% (p = 0.04). No relation between aPL and severe preeclampsia was found. CONCLUSION: The prevalence of aPL among women with preeclampsia is low. aPL can predispose women without risk factors to preeclampsia.